Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Drug Royalty Corporation (DRI-TSE) -- Ignore unavailable to you. Want to Upgrade?

To: zwing_88 who wrote (94)	5/13/2000 4:31:00 PM
From: thewiz	Read Replies (1) \| Respond to of 96

The recent surge in biotech stocks was exciting. Too bad, it didn't last. Take a glance at Drug Royalty [DRI.TO] - a venture capital firm that invests in the royalty stream of established drugs. And unlike many of the other emerging biotech stocks, DRI actually makes money and is probably the least risky of the emerging biotech group, subject to debate of course. In the 2000Q2, revenues surged by 76% to $4.4 million, while profits skyrocketed by 96% to $0.8 million, or $0.02 per share. The above is taken from the weekend version of Stockformation.